Taysha: Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates
Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of -12.50% and 4.54%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Read full article »
Taysha is a Texas-based biotechnology company that researches and develops gene therapies for the treatment of monogenic central nervous system disorders.
Read more